LY2228820

LY2228820 · Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for LY2228820, covering 2017-05-24 to 2020-03-24. Get the full timeline:

Most recent: Clinical Trial Update: A Study of LY2228820 in Participants With Advanced Cancer [Phase 1]